Boston Scientific Corp. made its $25 billion bid for heart devices maker Guidant Corp. official on Sunday, but rival bidder Johnson & Johnson reiterated that it is committed to buying Guidant itself.

Natick, Mass.-based Boston Scientific, which last month indicated it would launch a competing bid for the approved $21 billion deal with J&J, said it would pay $72 a share for Boston Scientific, divided evenly between cash and stock.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]